DNDN is at a different stage than Prima so you can't really say...

DNDN is at a different stage than Prima so you can't really say a small move there will affect it here.

DNDN has made many mistakes (as you would expect with anyone that is first to market). They have had recent problems with manufacture and the share price suffered but long term outlook is great for them. It's always easier to be second when it comes to these things as you can learn from the other's mistakes.

In relation to drugs and approval...most fail for failing to meet end points or have severe side effects.
Eg. Stimuvax has been halted as a patient experienced brain inflammation. Always hard to determine the cause as there is a few factors involved including the drug, chemo and the cancer.

Prima has very very minimal side effects. None at all serious to-date.

In terms if meeting end points of prolonged survival, this will be key if Prima is to succeed.

So far it is known that CVac produces an immune response on Mucin-1 100% of the time. And the stabilization of CA 125 levels in 47% of patients in phase 2a. With a decline in CA 125 levels in 4 of the 28 patients. That is remarkable and shows all signs of a blockbuster drug!